Plain-English translation of NCT06142396 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing daratumumab — a newer cancer-fighting drug — combined with three other medications (cyclophosphamide, bortezomib, and dexamethasone) for people who have just been diagnosed with multiple myeloma and have kidney problems. Multiple myeloma is a blood cancer that can damage the kidneys, making treatment tricky. The goal is to see if this medication combination can treat the cancer effectively while also helping the kidneys recover.
When multiple myeloma is diagnosed, about 20–50% of patients also have kidney damage, which makes their cancer harder to treat and their outlook worse. Most clinical trials have excluded these patients, leaving fewer proven treatment options. This study exists to test whether this newer treatment approach works safely and effectively for this overlooked group of patients.
You likely qualify if…
You likely don't qualify if…
You will receive the medication combination as an inpatient or outpatient over four 28-day cycles (roughly 4 months). During this time, you will have regular blood tests, scans, and bone marrow evaluations to see how well the treatment is working. After the first four cycles, your doctor will decide whether you need a stem cell transplant or additional cycles of the same medication, followed by 2 years of maintenance therapy with a different drug. You will be seen by the study team every three months for up to 2 years to monitor how you are doing.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States